Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

Clinical trial NCT03295227 · RECRUITING

Trial details

NCT number: NCT03295227
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Stage III Thymoma AJCC v8 Stage IIIA Thymoma AJCC v8 Stage IIIB Thymoma AJCC v8 Stage IV Thymoma AJCC v8 Stage IVA Thymoma AJCC v8 Stage IVB Thymoma AJCC v8 Unresectable Thymic Carcinoma

Start date: 2017-12-06
Primary completion: 2027-12-31
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.